×
0 0.00298507462686571 -0.0040298507462686 -0.00417910447761196 -0.00731343283582082 -0.011276119402985 -0.014179104477612 -0.0131477611940298
Stock impact report

AbbVie terminates late-stage lung cancer trial [Reuters]

AbbVie, Inc (ABBV)  More Company Research Source: Reuters
Last abbvie, inc earnings: 11/1 07:47 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF AbbVie terminates late-stage lung cancer trial (Reuters) - AbbVie Inc on Thursday said it will discontinue the late-stage trial testing its experimental treatment for a type of lung cancer after it failed to show a survival benefit compared to placebo. An independent data monitoring committee recommended terminating the trial after an interim analysis of data from the trial testing its treatment, Rova-T, as first-line therapy, the company said. AbbVie last year halted enrollment in a trial testing Rova-T as a second-line therapy in lung cancer. Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli Our Standards: The Thomson Reuters Trust Principles. [Read more]
Impact snapshot Event time: ABBV
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ABBV alerts
from News Quantified
Opt-in for
ABBV alerts

from News Quantified
Opt-in for
ABBV alerts

from News Quantified